Literature DB >> 19468022

Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction.

Thomas Bitter1, Lothar Faber, Detlef Hering, Christoph Langer, Dieter Horstkotte, Olaf Oldenburg.   

Abstract

AIMS: In patients with systolic heart failure (SHF) a high prevalence of sleep-disordered breathing (SDB) has been documented. The purpose of this study was to investigate the prevalence and type of SDB in patients with heart failure with normal left ventricular ejection fraction (HFNEF). METHODS AND
RESULTS: Two hundred and forty-four consecutive patients (87 women, aged 65.3 +/- 1.4 years) with HFNEF underwent capillary blood gas analysis, measurement of NT-proBNP concentrations, echocardiography, cardiopulmonary exercise testing (CPX), cardiorespiratory polygraphy, and simultaneous right and left heart catheterization. Sleep-disordered breathing was defined as an apnoea-hypopnoea-index (AHI) > or = 5/h. Sleep-disordered breathing was documented in 69.3% of all patients, 97 patients (39.8%) presented with OSA and 72 patients (29.5%) with CSA. With an increasing impairment of diastolic function the proportion of SDB, and CSA in particular, increased. Patients with SDB performed worse on CPX and six-minute walk test. Partial pressure of CO(2) was lower in CSA, whereas AHI, left atrial diameter, NT-proBNP, LVEDP, PAP, and PCWP were higher.
CONCLUSION: There is a high prevalence of SDB in HFNEF. In parallel to SHF, CSA patients in particular are characterized by a more impaired cardiopulmonary function. Whether SDB is of prognostic relevance in HFNEF needs to be determined.

Entities:  

Mesh:

Year:  2009        PMID: 19468022     DOI: 10.1093/eurjhf/hfp057

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  82 in total

1.  Relation of natriuretic peptide concentrations to central sleep apnea in patients with heart failure.

Authors:  Andrew D Calvin; Virend K Somers; Christelle van der Walt; Christopher G Scott; Lyle J Olson
Journal:  Chest       Date:  2011-06-02       Impact factor: 9.410

Review 2.  Phosphinic peptides as zinc metalloproteinase inhibitors.

Authors:  V Dive; D Georgiadis; M Matziari; A Makaritis; F Beau; P Cuniasse; A Yiotakis
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

3.  [Sleep-disordered breathing and atrial fibrillation].

Authors:  T Penzel; S Sogorski; J Zelmer; I Fietze; T Vogtmann; G Baumann; C Schöbel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-03

Review 4.  Sleep-disordered breathing and cardiovascular disorders.

Authors:  Rohit Budhiraja; Pooja Budhiraja; Stuart F Quan
Journal:  Respir Care       Date:  2010-10       Impact factor: 2.258

5.  [Sleep apnea and heart failure].

Authors:  T Plenge; J Müller-Ehmsen
Journal:  Herz       Date:  2013-09       Impact factor: 1.443

6.  The Sleep Apnea-Specific Hypoxic Burden Predicts Incident Heart Failure.

Authors:  Ali Azarbarzin; Scott A Sands; Luigi Taranto-Montemurro; Daniel Vena; Tamar Sofer; Sang-Wook Kim; Katie L Stone; David P White; Andrew Wellman; Susan Redline
Journal:  Chest       Date:  2020-04-13       Impact factor: 9.410

7.  Left atrial size, chemosensitivity, and central sleep apnea in heart failure.

Authors:  Andrew D Calvin; Virend K Somers; Bruce D Johnson; Christopher G Scott; Lyle J Olson
Journal:  Chest       Date:  2014-07       Impact factor: 9.410

Review 8.  Obstructive Sleep Apnea in Heart Failure: Review of Prevalence, Treatment with Continuous Positive Airway Pressure, and Prognosis.

Authors:  Himad K Khattak; Faisal Hayat; Salpy V Pamboukian; Harvey S Hahn; Brian P Schwartz; Phyllis K Stein
Journal:  Tex Heart Inst J       Date:  2018-06-01

Review 9.  Sleep apnea, heart failure, and pulmonary hypertension.

Authors:  Sogol Javaheri; Shahrokh Javaheri; Ali Javaheri
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 10.  Cheyne-stokes respiration in patients with heart failure.

Authors:  Laila AlDabal; Ahmed S BaHammam
Journal:  Lung       Date:  2009-12-03       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.